Literature DB >> 22458528

Systemic therapies for pancreatic cancer--the role of pharmacogenetics.

Ross A Soo1, Wei-Peng Yong, Federico Innocenti.   

Abstract

Effective systemic treatment of pancreatic cancer remains a major challenge, with progress hampered by drug resistance and treatment related toxicities. Currently available cytotoxic agents as monotherapy or in combination have provided only a modest survival benefit for patients with advanced disease. Disappointing phase III results with gemcitabine-based combinations in patients with advanced pancreatic cancer might be related to poor efficacy of systemic therapies in unselected patients. Future research strategies should prioritize identification of predictive markers through pharmacogenetic investigations. The individualization of patient treatment through pharmacogenetics may help to improve outcome by maximizing efficacy whilst lowering toxicity. This review provides an update on the pharmacogenetics of pancreatic cancer treatment and its influence on treatment benefits and toxicity.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22458528      PMCID： PMC3795429          DOI： 10.2174/138945012800564068

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN： 1389-4501            Impact factor:   3.465


  183 in total

1.  ERCC1 codon 118 polymorphism is a useful prognostic marker in patients with pancreatic cancer treated with platinum-based chemotherapy.

Authors:  Hirotaka Kamikozuru; Hidekazu Kuramochi; Kazuhiko Hayashi; Go Nakajima; Masakazu Yamamoto
Journal:  Int J Oncol       Date:  2008-05       Impact factor: 5.650

2.  Single-nucleotide polymorphisms of DNA damage response genes are associated with overall survival in patients with pancreatic cancer.

Authors:  Taro Okazaki; Li Jiao; Ping Chang; Douglas B Evans; James L Abbruzzese; Donghui Li
Journal:  Clin Cancer Res       Date:  2008-04-01       Impact factor: 12.531

3.  Cancer statistics, 2008.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Taylor Murray; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2008-02-20       Impact factor: 508.702

4.  Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.

Authors:  Bryan P Schneider; Molin Wang; Milan Radovich; George W Sledge; Sunil Badve; Ann Thor; David A Flockhart; Bradley Hancock; Nancy Davidson; Julie Gralow; Maura Dickler; Edith A Perez; Melody Cobleigh; Tamara Shenkier; Susan Edgerton; Kathy D Miller
Journal:  J Clin Oncol       Date:  2008-10-01       Impact factor: 44.544

Review 5.  Diverse molecular functions of Hu proteins.

Authors:  M N Hinman; H Lou
Journal:  Cell Mol Life Sci       Date:  2008-10       Impact factor: 9.261

6.  A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable?

Authors:  Andrew H Ko; Elizabeth Dito; Brian Schillinger; Alan P Venook; Zhidong Xu; Emily K Bergsland; Derrick Wong; Janet Scott; Jimmy Hwang; Margaret A Tempero
Journal:  Invest New Drugs       Date:  2008-04-01       Impact factor: 3.850

7.  HMGA1 is a molecular determinant of chemoresistance to gemcitabine in pancreatic adenocarcinoma.

Authors:  Siong-Seng Liau; Edward Whang
Journal:  Clin Cancer Res       Date:  2008-03-01       Impact factor: 12.531

8.  Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial.

Authors:  William F Regine; Kathryn A Winter; Ross A Abrams; Howard Safran; John P Hoffman; Andre Konski; Al B Benson; John S Macdonald; Mahesh R Kudrimoti; Mitchel L Fromm; Michael G Haddock; Paul Schaefer; Christopher G Willett; Tyvin A Rich
Journal:  JAMA       Date:  2008-03-05       Impact factor: 56.272

9.  High intratumoral dihydropyrimidine dehydrogenase mRNA levels in pancreatic cancer associated with a high rate of response to S-1.

Authors:  Hidekazu Kuramochi; Kazuhiko Hayashi; Kazumi Uchida; Go Nakajima; Takashi Hatori; Kathleen D Danenberg; Peter V Danenberg; Masakazu Yamamoto
Journal:  Cancer Chemother Pharmacol       Date:  2008-02-29       Impact factor: 3.333

10.  Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer.

Authors:  Volker Heinemann; Stefan Boeck; Axel Hinke; Roberto Labianca; Christophe Louvet
Journal:  BMC Cancer       Date:  2008-03-28       Impact factor: 4.430
View more
  8 in total

1.  Exploring predictive biomarkers from clinical genome-wide association studies via multidimensional hierarchical mixture models.

Authors:  Takahiro Otani; Hisashi Noma; Shonosuke Sugasawa; Aya Kuchiba; Atsushi Goto; Taiki Yamaji; Yuta Kochi; Motoki Iwasaki; Shigeyuki Matsui; Tatsuhiko Tsunoda
Journal:  Eur J Hum Genet       Date:  2018-09-10       Impact factor: 4.246

2.  Moving away from candidate genes: a 'genome-wise' discovery of gemcitabine myelotoxicity.

Authors:  Federico Innocenti
Journal:  Pharmacogenomics       Date:  2012-07       Impact factor: 2.533

3.  Multifaceted peptide assisted one-pot synthesis of gold nanoparticles for plectin-1 targeted gemcitabine delivery in pancreatic cancer.

Authors:  Krishnendu Pal; Farah Al-Suraih; Roberto Gonzalez-Rodriguez; Shamit Kumar Dutta; Enfeng Wang; H Shaun Kwak; Thomas R Caulfield; Jeffery L Coffer; Santanu Bhattacharya
Journal:  Nanoscale       Date:  2017-10-19       Impact factor: 7.790

4.  Minnelide Overcomes Oxaliplatin Resistance by Downregulating the DNA Repair Pathway in Pancreatic Cancer.

Authors:  Shrey Modi; Devika Kir; Bhuwan Giri; Kaustav Majumder; Nivedita Arora; Vikas Dudeja; Sulagna Banerjee; Ashok K Saluja
Journal:  J Gastrointest Surg       Date:  2015-10-26       Impact factor: 3.452

5.  Overexpression of heat shock protein 27 (HSP27) increases gemcitabine sensitivity in pancreatic cancer cells through S-phase arrest and apoptosis.

Authors:  Yang Guo; Andreas Ziesch; Sandra Hocke; Eric Kampmann; Stephanie Ochs; Enrico N De Toni; Burkhard Göke; Eike Gallmeier
Journal:  J Cell Mol Med       Date:  2014-10-21       Impact factor: 5.310

Review 6.  Detecting circulating tumor material and digital pathology imaging during pancreatic cancer progression.

Authors:  Radim Moravec; Rao Divi; Mukesh Verma
Journal:  World J Gastrointest Oncol       Date:  2017-06-15

7.  Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer.

Authors:  Linnéa Malgerud; Johan Lindberg; Valtteri Wirta; Maria Gustafsson-Liljefors; Masoud Karimi; Carlos Fernández Moro; Katrin Stecker; Alexander Picker; Carolin Huelsewig; Martin Stein; Regina Bohnert; Marco Del Chiaro; Stephan L Haas; Rainer L Heuchel; Johan Permert; Markus J Maeurer; Stephan Brock; Caroline S Verbeke; Lars Engstrand; David B Jackson; Henrik Grönberg; Johannes Matthias Löhr
Journal:  Mol Oncol       Date:  2017-08-08       Impact factor: 6.603

8.  A Novel E2F1-EP300-VMP1 Pathway Mediates Gemcitabine-Induced Autophagy in Pancreatic Cancer Cells Carrying Oncogenic KRAS.

Authors:  Alejandro Ropolo; Cintia Catrinacio; Felipe Javier Renna; Veronica Boggio; Tamara Orquera; Claudio D Gonzalez; Maria I Vaccaro
Journal:  Front Endocrinol (Lausanne)       Date:  2020-06-23       Impact factor: 5.555
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.